Literature DB >> 8163510

Purification, properties, and kinetics of enzymatic acylation with beta-lactams of soluble penicillin-binding protein 2a. A major factor in methicillin-resistant Staphylococcus aureus.

S Roychoudhury1, J E Dotzlaf, S Ghag, W K Yeh.   

Abstract

Intrinsic resistance toward beta-lactams in methicillin-resistant Staphylococcus aureus strains, a major source of nosocomial infections, is believed to be caused mainly by penicillin-binding protein 2a (PBP2a). This protein resembles other penicillin-binding proteins that are involved in bacterial cell wall biosynthesis and are the targets of active site acylation by beta-lactam antibiotics. PBP2a, however, presumably remains active at therapeutic concentrations of beta-lactams. In this paper, we describe a three-step purification of a soluble form of PBP2a (PBP2a') to apparent homogeneity using anion-and cation-exchange, and dye-ligand affinity chromatographies. Purified PBP2a' was a 74-kDa monomeric protein that appeared to be folded. The protein was evaluated for its enzymatic acylation with beta-lactams initially by fluorescence quenching and then kinetically by radioactive labeling. Using a modified 125I-labeled penicillin V-acylation assay, the apparent Km of PBP2a' for penicillin V was 1.2 mM. Three other beta-lactams, each of which exhibited significant fluorescence quenching, acted as strong competitive inhibitors of penicillin V with apparent Ki values of 123.4, 36.1, and 12.4 microM, respectively. By a new beta-lactam preincubation analysis, these compounds could function as substrates with similar Km values. Also, the acylation rates of different beta-lactams could be readily ascertained. The enzymatic acylation data substantiate the major causative role of PBP2a in the bacterial resistance. The quantitative radioactive acylation assays are potentially useful in screening for a potent inhibitor of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163510

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Specific interaction between beta-lactams and soluble penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: development of a chromogenic assay.

Authors:  S Roychoudhury; R E Kaiser; D N Brems; W K Yeh
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Glycosyltransferase domain of penicillin-binding protein 2a from Streptococcus pneumoniae is membrane associated.

Authors:  A M di Guilmi; N Mouz; L Martin; J Hoskins; S R Jaskunas; O Dideberg; T Vernet
Journal:  J Bacteriol       Date:  1999-05       Impact factor: 3.490

3.  Reaction of soluble penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus with beta-lactams and acyclic substrates: kinetics in homogeneous solution.

Authors:  K Graves-Woodward; R F Pratt
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

4.  RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases.

Authors:  Francois Malouin; Johanne Blais; Suzanne Chamberland; Monica Hoang; Craig Park; Christin Chan; Kristina Mathias; Samia Hakem; Kelly Dupree; Eric Liu; Tien Nguyen; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococci.

Authors:  B E Domaracki; A Evans; K E Preston; H Fraimow; R A Venezia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

6.  Rapid MRSA detection via tandem mass spectrometry of the intact 80 kDa PBP2a resistance protein.

Authors:  Jason R Neil; Arvind Verma; Scott R Kronewitter; William M McGee; Christopher Mullen; Marjaana Viirtola; Annika Kotovuori; Herdis Friedrich; Johan Finell; Joni Rannisto; John E P Syka; James L Stephenson
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.